Skip to content

Fighting to Preserve the Benefits of the 340B Program

Facebook page opens in new windowX page opens in new windowLinkedin page opens in new windowMail page opens in new window
RWC-340B
Ryan White Clinics for 340B Access
RWC-340B
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • Get The Facts
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
  • News
  • About Us
    • RWC-340B Principles
Search:
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • Get The Facts
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
  • News
  • About Us
    • RWC-340B Principles

CMS Defers Decision on Part D 340B Modifier Proposal

Drug Pricing, Medicaid, NewsBy Amber TynanJanuary 5, 2024

CMS published revised guidance on December 14, 2023 to defer its decision to require 340B point-of-sale modifiers for Part D drugs beginning in 2026. RWC-340B submitted comments to CMS’s initial proposal…

GAO Issues Report Criticizing HHS’ Oversight of 340B Duplicate Discounts

Drug Pricing, HHS, HRSA, Medicaid, RWC-340BBy adminJanuary 31, 2020

On January 27, 2020, the U.S. Government Accountability Office (GAO) released a report (the Report) assessing oversight by the Department of Health and Human Services (HHS) of the 340B duplicate…

CMS Issues Informational Bulletin on State Duplicate Discount Practices

Drug Pricing, HHS, Medicaid, News, RWC-340BBy adminJanuary 13, 2020

On January 8, 2020, the Centers for Medicare & Medicaid Services (CMS) issued an Informational Bulletin (Bulletin) outlining CMS’s view of current “best practices” by states to avoid 340B duplicate…

Senate Finance Committee Approves Major Drug Pricing Bill

Congress, Drug Pricing, Medicaid, News, RWC-340BBy adminJuly 25, 2019

On Thursday, July 25, 2019, the Senate Finance Committee voted to approve a wide-ranging drug pricing bill, the Prescription Drug Pricing Reduction Act (PDPRA) of 2019.  The bill seeks to…

Final Rule Will Require Drug Manufacturers to Disclose Prices in TV Advertisements

Drug Pricing, HHS, HIV/AIDS, Medicaid, News, Rulings, RWC-340BBy adminMay 8, 2019

Earlier today, HHS issued a Final Rule that will require pharmaceutical manufacturers to disclose the wholesale acquisition cost (“WAC”) in direct-to-consumer TV advertisements for all Medicare and Medicaid covered drugs. …

California Medicaid Will Transition All Pharmacy Services to Fee-for-Service

Medicaid, News, RegulationsBy adminJanuary 11, 2019

On January 7, California Gov. Gavin Newsom signed an executive order instructing Medi-Cal to transition all pharmacy services for Medi-Cal managed care to fee-for-service (FFS) by January 2021.  The directive…

CMS Finalizes Part B Cuts for 340B Drugs

MedicaidBy adminNovember 2, 2017

CMS finalized yesterday a nearly 30 percent cut in Medicare Part B reimbursement to hospitals for 340B physician-administered drugs.  The payment cut will go into effect January 1, 2018.  Currently,…

CMS Releases Covered Outpatient Drug Rule; Clarifies 340B in Managed Care

Medicaid, RWC-340BBy adminFebruary 1, 2016

The Centers for Medicare and Medicaid Services (CMS) issued its long awaited regulations on Medicaid reimbursement and rebates for so-called “covered outpatient drugs” today.  The rule is relevant to RWCs because drug manufacturers…

                                                                            © 2021 Ryan White Clinics for 340B Access. RWC-340B is a 501(c)(4) non-profit corporation.
Go to Top
Translate »
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset